Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

CEBP Focus: Update on Lymphoma

Benzene Exposure and Risk of Non-Hodgkin Lymphoma

Martyn T. Smith, Rachael M. Jones and Allan H. Smith
Martyn T. Smith
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachael M. Jones
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Allan H. Smith
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1055-9965.EPI-06-1057 Published March 2007
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Exposure to benzene, an important industrial chemical and component of gasoline, is a widely recognized cause of leukemia, but its association with non-Hodgkin lymphoma (NHL) is less clear. To clarify this issue, we undertook a systematic review of all case-control and cohort studies that identified probable occupational exposures to benzene and NHL morbidity or mortality. We identified 43 case-control studies of NHL outcomes that recognized persons with probable occupational exposure to benzene. Forty of these 43 (93%) studies show some elevation of NHL risk, with 23 of 43 (53%) studies finding statistically significant associations between NHL risk and probable benzene exposure. We also identified 26 studies of petroleum refinery workers reporting morbidity or mortality for lymphomas and all neoplasms and found that in 23 (88%), the rate of lymphoma morbidity or mortality was higher than that for all neoplasms. A substantial healthy-worker effect was evident in many of the studies and a comprehensive reevaluation of these studies with appropriate adjustments should be undertaken. Numerous studies have also reported associations between benzene exposure and the induction of lymphomas in mice. Further, because benzene is similar to alkylating drugs and radiation in producing leukemia, it is plausible that it might also produce lymphoma as they do and by similar mechanisms. Potential mechanisms include immunotoxicity and the induction of double-strand breaks with subsequent chromosome damage resulting in translocations and deletions. We conclude that, overall, the evidence supports an association between occupational benzene exposure and NHL. (Cancer Epidemiol Biomarkers Prev 2007;16(3):385–91)

  • Solvents
  • NHL
  • Refinery
  • Epidemiology
  • Hematology

Introduction

Benzene is an important industrial chemical, as evidenced by production in excess of 2 billion gallons annually in the United States, and is a component of gasoline. Workers in a number of industries, including petroleum refining, shipping, rubber manufacturing, automobile repair, and shoe manufacturing, are potentially exposed to high levels of benzene. Benzene exposures among the general public are lower than most occupational exposures and result from cigarette smoking, gasoline use, and automobile emissions. Although benzene is a widely recognized cause of leukemia, the association of benzene with non-Hodgkin lymphoma (NHL) is less clear. Given the prevalence of benzene exposure and the potential for benzene to produce chromosome changes and other genetic changes of importance in NHL induction, it is essential to clarify the association between benzene exposure and NHL. Accurate quantification of the burden of benzene-associated diseases is necessary to evaluate the health risk posed by environmental contamination and occupational exposures at current exposure limits. Toward this aim, we undertook a review of all case-control and cohort studies that identified probable occupational exposures to benzene and NHL morbidity or mortality and concluded that the evidence supports an association between occupational benzene exposure and NHL.

Early Case Reports of Benzene-Induced Lymphoma

In the early 1900s, benzene was widely used as an industrial solvent and through the appearance of multiple reports in the literature of anemia, pancytopenia, and leukemia, its toxicity to the blood and bone marrow quickly became manifest. French investigators were the first to report a case of lymphoma associated with benzene exposure in 1947 (1). Similar reports emerged in the 1960s from France, Italy, and Spain. Studies in Turkish shoe workers by Aksoy and others in the 1970s and 1980s were instrumental in establishing the relationship between benzene and leukemia, but these studies also identified 11 cases of lymphoma associated with occupational benzene exposure (2). They concluded that benzene could cause a variety of hematologic and lymphatic malignancies, in addition to damaging the bone marrow.

Solvent Exposure and NHL

As highlighted in this issue by Vineis and coworkers, occupational exposure to solvents has been associated with an increased risk of NHL in numerous studies. In their review on the topic, Rego et al. (3) considered that 72% of studies with an accurate definition of solvent exposure observed positive associations between solvent exposures and NHL. Solvents, however, are chemically diverse and often exist as chemical mixtures, which makes it difficult to incriminate a specific chemical agent (4). Given the association of benzene with disorders of the bone marrow and blood, and the ability of the chemical to produce chromosomal and genetic changes important to NHL induction, it is plausible that benzene is a specific solvent associated with NHL.

Review of Case-Control Studies with Probable Benzene Exposure

We identified 43 case-control studies of NHL outcomes that recognized persons with probable occupational exposure to benzene. Forty of these 43 (93%) studies show some elevation of NHL risk, with 23 of 43 (53%) studies finding statistically significant associations between NHL risk and probable benzene exposure (Supplementary Table S1). Slightly more than half of these studies, 22 in total, specifically looked at benzene exposure and are described in Table 1 . Of these 22 studies, 17 (77%) show some elevation of NHL risk, with 8 of 22 (36%) finding statistically significant associations between NHL risk and benzene exposure. The eight studies showing increased risks are diverse in nature and include the recent study of Miligi, Vineis, Costantini, and colleagues, who described an increased risk of NHL with exposure to aromatic hydrocarbon solvents of 2.1 (1.1-4.3; ref. 5). Medium/high exposure to benzene-containing solvents elevated the risk of NHL [odds ratio (OR), 1.6; 95% confidence interval (95% CI), 1.0-2.4], especially diffuse NHL (OR, 2.4; 95% CI, 1.3-4.5; Table 1; ref. 5). They update and extend their findings elsewhere in this issue.

View this table:
  • View inline
  • View popup
Table 1.

Case control studies of NHL with benzene exposure

Dryver et al. (6) found increased risks of NHL for exposures to aromatic hydrocarbon solvents and gasoline (OR, 1.72; 95% CI, 1.10-2.71; ref. 6), including dose-dependent effects for exposure to aromatic hydrocarbon solvents and duration-dependent effects for gasoline. Risks were also significantly increased for employment as an automobile mechanic, gas station attendant, and painter or varnisher. Blair et al. (7) observed that increased risks of diffuse and follicular NHL were associated with increased benzene exposure intensity and were significantly increased among both painters and persons with metal exposures.

Fabbro-Perray et al. (8) identified an association between self-reported benzene exposure and increased risk of NHL (OR 2.0; 95% CI, 1.1-3.9) that was especially strong for those exposed for >810 days (Table 1). Hardell et al. (9) reported increased risks of lymphoma in workers with high exposures to benzene, styrene, and chlorinated solvents (RR, 4.5; 95% CI, 1.9-11.4). Following up this study, Hardell et al. (10) observed large increases in NHL risk (OR, 28; 95% CI, 1.8-730) subsequent to benzene exposure; smaller, but significant, risks of NHL were observed for exposure to degreasers and organic solvents (Table 1).

Ott et al. (11) found elevated risks of NHL in foremen and others who had long careers in maintenance and construction work at chemical facilities. In particular, male workers with >5 years of occupational exposure to benzene had a 1.6-fold elevated risk of NHL. Xu et al. (12) found statistically significant excesses of lymphoma for exposure to benzene (adjusted OR, 2.78; P = 0.001) in a hospital-based study in China.

Cohort Studies of Refinery Workers

Petroleum refinery workers are potentially at risk of lymphoma and other cancers from exposure to benzene concentrated during the refining process. There have been many studies of workers in this industry, most of which have been conducted by industry-funded research groups. We identified 26 studies of petroleum refinery workers reporting morbidity or mortality for lymphomas and all (combined) neoplasms (Table 2 ). Lymphoma mortality or morbidity is significantly elevated in a few studies, but in most studies the rates are slightly but not significantly elevated. These slightly elevated rates, however, are striking because the studies report the population to have a deficit of mortality or morbidity from all (combined) neoplasms or all causes. Deficits in mortality and morbidity in cohorts of workers are often identified as the “healthy-worker effect.” The healthy-worker effect, however, would predict that the workers experience deficits in mortality and morbidity from all causes: morbidity and mortality rates near those experienced by the general population or white-collar workers are suggestive of adverse health effects from occupational exposures. Among the 26 studies reporting mortality or morbidity from all neoplasms and from NHL, 23 (88%) showed that the rate of lymphoma morbidity or mortality was higher than that for all neoplasms. A similar trend appears for studies reporting all-cause mortality: the rate of lymphoma mortality is greater than the rate of all-cause mortality in 14 of 17 (82%) of studies reporting both outcomes.

View this table:
  • View inline
  • View popup
Table 2.

Cohort studies in the petroleum refining industry with non-Hodgkin lymphoma outcomes

We explored this remarkably consistent finding further by adjusting for the healthy-worker effect in the study of Dagg et al. (13). Miettinen and Wang (14) proposed analyzing proportionate mortality studies as case-control studies to yield an odds ratio estimate. The same approach can be used to adjust for the healthy-worker effect. The standardized mortality ratio for lymphatic and hematopoietic cancers was not significantly elevated at 107 (95% CI, 86-132) without adjustment in this study, but the standardized mortality ratio for all causes of death was 73 (95% CI, 71-76), showing clear evidence of a healthy-worker effect. To adjust for the health worker effect, we considered lymphatic and hematopoietic cancers to be cases, and all other causes of death excluding lymphatic and hematopoietic cancers as controls. The OR for lymphatic and hematopoietic cancers estimated using Miettinen's method (14) was 1.48 (95% CI, 1.20-1.83; P < 0.001), providing clear evidence that the healthy worker effect masked increased blood cancer risks. Many cohort studies of refinery workers in Table 2, like the study by Dagg et al. (13), show reduced standardized mortality ratios for all neoplasms combined, suggesting that masking of NHL risk by the healthy-worker effect is common. A comprehensive reevaluation of these studies with appropriate adjustments should be undertaken.

Studies of Other Worker Cohorts

A study of benzene-exposed workers in China, conducted by investigators from the U.S. National Cancer Institute and the Chinese Academy of Preventive Medicine, is ongoing (15). To date, the primary NHL-related finding from the ∼74,000 observed workers is a 3-fold increase in NHL risk for benzene-exposed workers, increasing to a 4-fold excess in NHL risk for workers exposed to benzene for 10 or more years. For workers in the chemical industry in this cohort, the relative risk (RR) was even higher at 7.8. In a study of chemical industry workers in the United States, Wong (16) found that the RR for NHL mortality among white benzene-exposed workers was 8.6 (P = 0.02) compared with unexposed workers. For workers continuously exposed to benzene, the RR was 9.6 compared with unexposed workers. Cohort studies of workers in the chemical manufacturing industry are summarized in Supplementary Table S2.

Studies of worker cohorts in the rubber industry, like the petroleum refining and chemical industries, have found elevated risks of lymphatic and hematopoietic malignancies (Supplementary Table S3). The role of benzene in these cancers, however, can be difficult to define because workers in this industry are often exposed to other potential carcinogens, such as 1,3-butadiene. The only study of rubber workers in which it is widely agreed that the only significant solvent exposure was benzene is the Pliofilm study of rubber hydrochloride workers (17, 18). Although significantly elevated risks for leukemia and multiple myeloma were observed, an elevated risk for NHL was not. The failure of this study to identify an association between benzene exposure and NHL mortality, however, does not exclude the possibility of the association. In particular, the low mortality and long latency of NHL severely limited the power of the Pliofilm study to detect an association between benzene-exposure and NHL mortality. We note that the 5-year survival of NHL and lymphocytic leukemias exceeds 60%, compared with <20% for acute leukemia and myeloma. This explains why the expected number of deaths from NHL in the Pliofilm cohort was less than those expected from acute leukemia, although the incidence of NHL is four to five times that of leukemia. Further, the typical latency period for NHL is likely to be much longer than that for acute leukemia. Thus, the Pliofilm study has limited power to detect elevated risks of NHL following benzene exposure.

Elevated Risks of Chronic Lymphocytic Leukemia

B-cell chronic lymphocytic leukemia is now classified together with small lymphocytic lymphoma as a form of NHL. A number of studies show elevated risks of chronic lymphocytic leukemia at relatively low levels of benzene exposure (Supplementary Table S1). The most notable is that of Glass et al. (19), but others have also showed elevated risks including studies in the United Kingdom of petroleum distribution workers (20).

Other Evidence Supporting an Association between Benzene Exposure and Lymphoma

Numerous studies have reported associations between benzene exposure and the induction of lymphomas in mice. Studies by Cronkite et al. (21) and Snyder et al. (22) in the early 1980s showed inhalation of benzene caused excess lymphomas in various mouse strains. The 1986 National Toxicology Program carcinogenicity bioassay of benzene also reported an excess of malignant lymphomas, as well as other cancers, in male and female B6C3F1 mice. Studies in Italy by Maltoni et al. (23) showed excesses of lymphosarcomas in RF/J mice. As with many rodent toxicology studies, there has been debate over the relevance of these findings to humans.

There are many similarities between leukemia induced by benzene and that induced by chemotherapy with alkylating agents, so-called therapy-related leukemia, and the latter has been proposed as a model of chemical-induced leukemogenesis (24). Treatment of primary cancers with alkylating agents such as melphalan dramatically increases risks of secondary leukemias. Interestingly, as discussed by Krishnan and Morgan in this issue, numerous studies show that alkylating agent chemotherapy also increases the risk of secondary NHL as well as leukemia. Thus, benzene may act like alkylating agents and ionizing radiation in inducing both leukemias and lymphomas.

Conclusions

A comprehensive review of all case-control and cohort studies that identified probable occupational exposures to benzene and NHL morbidity or mortality showed evidence of an association between occupational benzene exposure and NHL. Studies in experimental animals and of therapy-related lymphoma in the clinical setting support this finding. Potential mechanisms for lymphoma induction by benzene include immunotoxicity and chromosomal damage resulting in translocations and deletions. Further work is needed to elucidate these mechanisms.

Footnotes

  • Grant support: Northern California Center for Occupational and Environmental Health and NIH grants P42ES04705, R01ES06721, and R01CA104862 (M.T. Smith) and National Institute for Occupational Safety and Health Training Grant T42 OH008429 (R.M. Jones).

  • Note: Supplementary data for this article are available at Cancer Epidemiology Biomakers and Prevention Online (http://cebp.aacrjournals.org/).

    M.T.S. has received consulting and expert testimony fees from law firms representing both plaintiffs and defendants in cases involving exposure to benzene.

    • Accepted December 20, 2006.
    • Received December 15, 2006.

References

  1. ↵
    Bousser JR, Neyde R, Fabre A. Un cas hemopathie benzolique tres returdee a type lymposarcome. Bull Mem Soc Med Hop Paris 1947;63:1100.
  2. ↵
    Aksoy M. Benzene carcinogenicity. Benzene carcinogenicity. Boca Raton (FL): CRC Press, Inc.; 1988.
  3. ↵
    Rego MA, Sousa CS, Kato M, de Carvalho AB, Loomis D, Carvalho FM. Non-Hodgkin's lymphomas and organic solvents. J Occup Environ Med 2002;44:874–81.
    OpenUrlPubMed
  4. ↵
    Weisenburger DD. Epidemiology of non-Hodgkin's lymphoma: recent findings regarding an emerging epidemic. Ann Oncol 1994;5 Suppl 1:19–24.
    OpenUrlFREE Full Text
  5. ↵
    Miligi L, Costantini AS, Benvenuti A, et al. Occupational exposure to solvents and the risk of lymphomas. Epidemiology 2006;17:552–61.
    OpenUrlCrossRefPubMed
  6. ↵
    Dryver E, Brandt L, Kauppinen T, Olsson H. Occupational exposures and non-Hodgkin's lymphoma in Southern Sweden. Int J Occup Environ Health 2004;10:13–21.
    OpenUrlPubMed
  7. ↵
    Blair A, Linos A, Stewart PA, et al. Evaluation of risks for non-Hodgkin's lymphoma by occupation and industry exposures from a case-control study. Am J Ind Med 1993;23:301–12.
    OpenUrlPubMed
  8. ↵
    Fabbro-Peray P, Daures JP, Rossi JF. Environmental risk factors for non-Hodgkin's lymphoma: a population-based case-control study in Languedoc-Roussillon, France. Cancer Causes Control 2001;12:201–12.
    OpenUrlCrossRefPubMed
  9. ↵
    Hardell L, Eriksson M, Lenner P, Lundgren E. Malignant lymphoma and exposure to chemicals, especially organic solvents, chlorophenols and phenoxy acids: a case-control study. Br J Cancer 1981;43:169–76.
    OpenUrlPubMed
  10. ↵
    Hardell L, Eriksson M, Degerman A. Exposure to phenoxyacetic acids, chlorophenols, or organic solvents in relation to histopathology, stage, and anatomical localization of non-Hodgkin's lymphoma. Cancer Res 1994;54:2386–9.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Ott MG, Teta MJ, Greenberg HL. Lymphatic and hematopoietic tissue cancer in a chemical manufacturing environment. Am J Ind Med 1989;16:631–43.
    OpenUrlPubMed
  12. ↵
    Xu CG, Zheng SP, Huang J, Wu JX. [A case-control study for assessing the relation between the incidence of malignant lymphomas and environmental factors in Sichuan province]. Zhonghua Liu Xing Bing Xue Za Zhi 2003;24:875–8.
    OpenUrlPubMed
  13. ↵
    Dagg TG, Satin KP, Bailey WJ, Wong O, Harmon LL, Swencicki RE. An updated cause specific mortality study of petroleum refinery workers. Br J Ind Med 1992;49:203–12.
    OpenUrlPubMed
  14. ↵
    Miettinen OS, Wang JD. An alternative to the proportionate mortality ratio. Am J Epidemiol 1981;114:144–8.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Hayes RB, Songnian Y, Dosemeci M, Linet M. Benzene and lymphohematopoietic malignancies in humans. Am J Ind Med 2001;40:117–26.
    OpenUrlCrossRefPubMed
  16. ↵
    Wong O. An industry wide mortality study of chemical workers occupationally exposed to benzene. I. General results. Br J Ind Med 1987;44:365–81.
    OpenUrlPubMed
  17. ↵
    Infante PF, Rinsky RA, Wagoner JK, Young RJ. Leukaemia in benzene workers. Lancet 1977;2:76–8.
    OpenUrlCrossRefPubMed
  18. ↵
    Rinsky RA, Hornung RW, Silver SR, Tseng CY. Benzene exposure and hematopoietic mortality: a long-term epidemiologic risk assessment. Am J Ind Med 2002;42:474–80.
    OpenUrlCrossRefPubMed
  19. ↵
    Glass DC, Gray CN, Jolley DJ, et al. Leukemia risk associated with low-level benzene exposure. Epidemiology 2003;14:569–77.
    OpenUrlCrossRefPubMed
  20. ↵
    Rushton L, Romaniuk H. A case-control study to investigate the risk of leukaemia associated with exposure to benzene in petroleum marketing and distribution workers in the United Kingdom. Occup Environ Med 1997;54:152–66.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Cronkite EP, Bullis J, Inoue T, Drew RT. Benzene inhalation produces leukemia in mice. Toxicol Appl Pharmacol 1984;75:358–61.
    OpenUrlCrossRefPubMed
  22. ↵
    Snyder CA, Goldstein BD, Sellakumar AR, Bromberg I, Laskin S, Albert RE. The inhalation toxicology of benzene: incidence of hematopoietic neoplasms and hematotoxicity in ARK/J and C57BL/6J mice. Toxicol Appl Pharmacol 1980;54:323–31.
    OpenUrlCrossRefPubMed
  23. ↵
    Maltoni C, Ciliberti A, Cotti G, Conti B, Belpoggi F. Benzene, an experimental multipotential carcinogen: results of the long-term bioassays performed at the Bologna Institute of Oncology. Environ Health Perspect 1989;82:109–24.
    OpenUrlPubMed
  24. ↵
    Larson RA, Le Beau MM. Therapy-related myeloid leukaemia: a model for leukemogenesis in humans. Chem Biol Interact 2005;153–4:187–95.
View Abstract
PreviousNext
Back to top
Cancer Epidemiology Biomarkers & Prevention: 16 (3)
March 2007
Volume 16, Issue 3
  • Table of Contents
  • Table of Contents (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Benzene Exposure and Risk of Non-Hodgkin Lymphoma
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Benzene Exposure and Risk of Non-Hodgkin Lymphoma
Martyn T. Smith, Rachael M. Jones and Allan H. Smith
Cancer Epidemiol Biomarkers Prev March 1 2007 (16) (3) 385-391; DOI: 10.1158/1055-9965.EPI-06-1057

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Benzene Exposure and Risk of Non-Hodgkin Lymphoma
Martyn T. Smith, Rachael M. Jones and Allan H. Smith
Cancer Epidemiol Biomarkers Prev March 1 2007 (16) (3) 385-391; DOI: 10.1158/1055-9965.EPI-06-1057
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Early Case Reports of Benzene-Induced Lymphoma
    • Solvent Exposure and NHL
    • Review of Case-Control Studies with Probable Benzene Exposure
    • Cohort Studies of Refinery Workers
    • Studies of Other Worker Cohorts
    • Elevated Risks of Chronic Lymphocytic Leukemia
    • Other Evidence Supporting an Association between Benzene Exposure and Lymphoma
    • Conclusions
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Environmental and Behavioral Factors and the Risk of Non-Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma Secondary to Cancer Chemotherapy
  • Exposure to Solvents and Risk of Non-Hodgkin Lymphoma: Clues on Putative Mechanisms
Show more CEBP Focus: Update on Lymphoma
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement